Sam Barrell, Özgür Tuncer, Purvi Thomson and many more share insights on the subjects that matter to healthcare professionals in October’s Healthcare Today Digest.

Rare diseases affect approximately 3.5 million people in the UK, a patient cohort equivalent to the national cancer population, yet one where only 5% of conditions have approved treatments. Beyond the human impact, recent MHRA estimates place the combined healthcare and wider economic cost of rare diseases to the UK at nearly £19.6 billion a year. 

Combined with the rising global threat of antimicrobial resistance, the imperative for targeted healthcare delivery has never been higher.

In this issue, LifeArc chief executive Sam Barrell breaks down why rare is not rare, how LifeArc is deploying £40 million into national rare disease trial acceleration centres, and what the UK must do to cement its position as a global life sciences hub.

Also, Stablepharma CEO Özgür Tuncer talks about vaccine wastage; OCL Vision’s head of optometry Purvi Thomson explains how community optometrists can deliver accessible front-line services; and much more…